PolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount
Company Expects to Extend Cash Runway into Q3 2023
PolyPid Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regulatory Authorities in Q1 2023
Related news for (PYPD)
- PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
- BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
- 24/7 Market News Snapshot 09 June, 2025 – PolyPid Ltd. Ordinary Shares (NASDAQ:PYPD)
- PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
- Breaking News: MoBot’s Latest Update as of 06/09/25 07:00 AM